[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69433889D1 - Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren - Google Patents

Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren

Info

Publication number
DE69433889D1
DE69433889D1 DE69433889T DE69433889T DE69433889D1 DE 69433889 D1 DE69433889 D1 DE 69433889D1 DE 69433889 T DE69433889 T DE 69433889T DE 69433889 T DE69433889 T DE 69433889T DE 69433889 D1 DE69433889 D1 DE 69433889D1
Authority
DE
Germany
Prior art keywords
tumors
treatment
administering
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433889T
Other languages
English (en)
Other versions
DE69433889T2 (de
Inventor
Martin J Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of DE69433889D1 publication Critical patent/DE69433889D1/de
Publication of DE69433889T2 publication Critical patent/DE69433889T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69433889T 1993-09-22 1994-09-19 Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren Expired - Fee Related DE69433889T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US125609 1993-09-22
US08/125,609 US5484612A (en) 1993-09-22 1993-09-22 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin

Publications (2)

Publication Number Publication Date
DE69433889D1 true DE69433889D1 (de) 2004-08-12
DE69433889T2 DE69433889T2 (de) 2005-06-30

Family

ID=22420569

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69424915T Expired - Fee Related DE69424915T2 (de) 1993-09-22 1994-09-19 Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
DE69433889T Expired - Fee Related DE69433889T2 (de) 1993-09-22 1994-09-19 Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69424915T Expired - Fee Related DE69424915T2 (de) 1993-09-22 1994-09-19 Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren

Country Status (22)

Country Link
US (4) US5484612A (de)
EP (2) EP0649658B1 (de)
JP (1) JPH07215882A (de)
KR (1) KR100383402B1 (de)
AT (2) ATE270553T1 (de)
AU (1) AU690132B2 (de)
CA (1) CA2132578C (de)
CZ (1) CZ289742B6 (de)
DE (2) DE69424915T2 (de)
DK (2) DK0972517T3 (de)
ES (2) ES2147567T3 (de)
GR (1) GR3034360T3 (de)
HU (1) HUT71119A (de)
IL (1) IL111025A (de)
MY (1) MY112405A (de)
NO (1) NO943524L (de)
NZ (2) NZ264502A (de)
PT (2) PT972517E (de)
RU (1) RU2148406C1 (de)
SG (1) SG52568A1 (de)
SK (1) SK282178B6 (de)
UA (1) UA49787C2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
ATE338553T1 (de) * 1997-03-07 2006-09-15 Sanofi Aventis Us Llc Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
JP2001523645A (ja) * 1997-11-14 2001-11-27 ザ・ゼネラル・ホスピタル・コーポレイション 血液学的疾患の処置
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6819761B1 (en) * 1999-09-16 2004-11-16 Silicon Laboratories, Inc. Programmable constant current “off hook” circuit
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ES2315245T3 (es) 1999-12-21 2009-04-01 Ufz-Umweltforschungszentrum Leipzig-Halle Gmbh Nueva 1,2,4-benzotriacina trisustituida y su procedimiento de produccion y su utilizacion.
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
WO2005082867A1 (en) * 2004-03-01 2005-09-09 Auckland Uniservices Limited Novel 1,2,4-benzotriazine-1,4-dioxides
DE602006018883D1 (de) * 2005-03-31 2011-01-27 Auckland Uniservices Ltd Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen
US20090136521A1 (en) * 2005-10-03 2009-05-28 Genetix Pharmaceuticals , Inc. Method for Selectively Depleting Hypoxic Cells
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
EP2404596A1 (de) * 2006-03-23 2012-01-11 TMRC Co., Ltd. Kit zur Krebsbehandlung und pharmazeutische Zusammensetzung zur Krebsbehandlung
US9789290B2 (en) * 2008-01-28 2017-10-17 Peter Forsell Drainage device comprising a filter cleaning device
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US9316632B2 (en) * 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de) 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
EP2800744A4 (de) * 2011-12-07 2015-06-03 Sri Internat Inc Benzotriazinoxide als arzneimittel gegen mycobacterium tuberculosis
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
AU2020300999A1 (en) * 2019-07-01 2022-02-17 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Also Published As

Publication number Publication date
DK0649658T3 (da) 2000-09-11
MY112405A (en) 2001-06-30
AU690132B2 (en) 1998-04-23
RU94034104A (ru) 1996-11-10
IL111025A (en) 2006-04-10
NO943524D0 (no) 1994-09-22
PT972517E (pt) 2004-11-30
SK282178B6 (sk) 2001-11-06
ES2147567T3 (es) 2000-09-16
HU9402726D0 (en) 1994-12-28
KR950007853A (ko) 1995-04-15
CA2132578C (en) 1998-10-13
KR100383402B1 (ko) 2003-09-22
CA2132578A1 (en) 1995-03-23
HUT71119A (en) 1995-11-28
JPH07215882A (ja) 1995-08-15
SG52568A1 (en) 1998-09-28
IL111025A0 (en) 1994-11-28
AU7411794A (en) 1995-04-06
CZ289742B6 (cs) 2002-03-13
DE69433889T2 (de) 2005-06-30
US5670502A (en) 1997-09-23
GR3034360T3 (en) 2000-12-29
DE69424915T2 (de) 2001-01-18
EP0972517B1 (de) 2004-07-07
EP0649658B1 (de) 2000-06-14
ES2224517T3 (es) 2005-03-01
NO943524L (no) 1995-03-23
DK0972517T3 (da) 2004-11-08
ATE270553T1 (de) 2004-07-15
CZ232694A3 (en) 1995-09-13
US6121263A (en) 2000-09-19
SK114894A3 (en) 1995-11-08
EP0649658A1 (de) 1995-04-26
ATE193827T1 (de) 2000-06-15
NZ264502A (en) 1997-06-24
PT649658E (pt) 2000-12-29
NZ299690A (en) 1997-11-24
UA49787C2 (uk) 2002-10-15
RU2148406C1 (ru) 2000-05-10
EP0972517A2 (de) 2000-01-19
US5484612A (en) 1996-01-16
US6277835B1 (en) 2001-08-21
DE69424915D1 (de) 2000-07-20
EP0972517A3 (de) 2000-01-26

Similar Documents

Publication Publication Date Title
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
TW229156B (de)
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
NO994330L (no) Metode for behandling av en tumor
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE69713273D1 (de) Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
JPS61155324A (ja) 癌治療薬剤
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
NO910033L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-3-fenoksypropylaminoforbindelser.
DE69633673D1 (de) Verwendung von Halofuginon zur Herstellung eines Medikaments zur Vorbeugung von Neovaskularisation und zur Behandlung bösartiger Tumore
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE354373T1 (de) Verabreichung von gammaglobulinen zur behandlung von lymphomen
DE69810332D1 (de) Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee